Informacje o członku

Dr Marta Morales Ballús
Hiszpania
Zespół

Dr Jaume Català Mora
Hiszpania

Dr Elisa Carreras
Hiszpania

Dr Itziar Alonso
Hiszpania

Dr Isabel Ayet
Hiszpania

Dr Ester Casas
Hiszpania

Optometrist Ana Díaz
Hiszpania

Dr Jesús Díaz
Hiszpania

Optometrist Enric Puigventos
Hiszpania

Optometrist Carles Fresno
Hiszpania

Dr Carmen García Vicuña
Hiszpania

Dr Hugo Gonzalez
Hiszpania

Optometrist Enrique Jimenez
Hiszpania

Dr Ana Llorca
Hiszpania

Dr Antonio Federico Martinez Monstseny
Hiszpania

Dr Joan Prat
Hiszpania

Dr Gemma Romeu
Hiszpania

Dr Alicia Serra
Hiszpania

Optometrist Simone Suh
Hiszpania

Dr Mariona Vidal
Hiszpania

Optometrist Begoña Yeste
Hiszpania

Dr Núria Planas
Hiszpania
Centrum HCP

skontaktuj się
Hospital Sant Joan de Déu, Spain
Badania kliniczne

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG

A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)

A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).

MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation